MK0646 is a monoclonal antibody that inhibits the insulin-like growth factor 1 receoptor (IGF-1R). It is administered intravenously.
MK0646 is under development by Merck. For information from the manufacturer, see the Merck website. Currently there is little information there other than a list of trials.
There are numerous trials with this drug, but no currently recruiting trials are relevant to GIST patients. Two trials now closed to recruitment were:
MK0646 is in a combination trial with an mTOR inhibitor, deforolimus:
A Combination Study With MK8669 (Deforolimus) and MK0646 in Patients With Advanced Cancer
MK0646 is in this single-agent Phase I trial:
Study of MK0646 in Patients With Solid Tumors